Direxion Daily Semicondct Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

MicroSectors Gold Miners 3X Leveraged ETN

ProShares UltraShort Silver

Direxion Daily Small Cap Bear 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

Guggenheim Solar ETF

VS TR 2x Long VIX Futures ETF

Direxion Daily Semicondct Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

ProShares Ultra Bloomberg Natural Gas

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

ProShares Ultra Silver

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

iShares MSCI Brazil Capped

United States Natural Gas

iShares FTSE China 25 Index Fun

Direxion Daily Small Cap Bull 3X ETF

Cleveland-Cliffs Inc. Common Stock

Unity Software Inc. Common Stock

Hims & Hers Health Inc. Class A Common Stock

Reliance Steel & Aluminum Co. Common Stock (DE)

TKO Group Holdings Inc. Class A Common Stock

Victorias Secret & Co. Common Stock

Spotify Technology S.A. Ordinary Shares

Dutch Bros Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Energizer Holdings Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Ciena Corporation Common Stock

Archer Aviation Inc. Class A Common Stock

C3.ai Inc. Class A Common Stock

Virgin Galactic Holdings Inc. Common Stock

Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Olin Corporation Common Stock

Civitas Resources Inc. Common Stock

Alcoa Corporation Common Stock

Click here to get full coverage on Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Yahoo Finance

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?  Yahoo Finance

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Yahoo Finance

Click here to get full coverage on (SRPT) Trading Report - news.stocktradersdaily.com

(SRPT) Trading Report  news.stocktradersdaily.com

(SRPT) Trading Report - news.stocktradersdaily.com

Click here to get full coverage on We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right  simplywall.st

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st

Click here to get full coverage on July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq

July 11th Options Now Available For Sarepta Therapeutics (SRPT)  Nasdaq

July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq

Click here to get full coverage on Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus

Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News  GuruFocus

Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus

Click here to get full coverage on SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm  FinancialContent

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

Click here to get full coverage on Goldman Sachs on Sarepta Therapeutics (SRPT): 'Elevidys' full approval is likely intact per CBER Director's commentary' - StreetInsider

Goldman Sachs on Sarepta Therapeutics (SRPT): 'Elevidys' full approval is likely intact per CBER Director's commentary'  StreetInsider

Goldman Sachs on Sarepta Therapeutics (SRPT): 'Elevidys' full approval is likely intact per CBER Director's commentary' - StreetInsider

Click here to get full coverage on SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Morningstar

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm  Morningstar

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Morningstar

Click here to get full coverage on Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Yahoo Finance

Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential  Yahoo Finance

Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why - Yahoo Finance

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why  Yahoo Finance

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why - Yahoo Finance

Click here to get full coverage on Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow - Yahoo Finance

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow  Yahoo Finance

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8% - Yahoo Finance

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%  Yahoo Finance

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8% - Yahoo Finance

Click here to get full coverage on Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? - Yahoo Finance

Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?  Yahoo Finance

Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? - Yahoo Finance

Click here to get full coverage on SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays  Yahoo Finance

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance

Click here to get full coverage on Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday - Yahoo Finance

Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday  Yahoo Finance

Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday - Yahoo Finance

Click here to get full coverage on SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Yahoo Finance

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut  Yahoo Finance

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Yahoo Finance

Click here to get full coverage on Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 - Yahoo Finance

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4  Yahoo Finance

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 - Yahoo Finance

Click here to get full coverage on 3 Reasons to Avoid SRPT and 1 Stock to Buy Instead - Yahoo Finance

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead  Yahoo Finance

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential - Yahoo Finance

Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential  Yahoo Finance

Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential - Yahoo Finance

Click here to get full coverage on Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? - Yahoo Finance

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?  Yahoo Finance

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? - Yahoo Finance

Click here to get full coverage on Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT) - Yahoo Finance

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)  Yahoo Finance

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT) - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates  Yahoo Finance

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation - Nasdaq

Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation  Nasdaq

Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation - Nasdaq

Click here to get full coverage on Why Sarepta Therapeutics (SRPT) Stock Is Nosediving - Yahoo Finance

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving  Yahoo Finance

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving - Yahoo Finance

Click here to get full coverage on Sarepta Earnings: Record $745M Revenue Quarter Overshadowed by Slashed Sales Forecast - Stock Titan

Sarepta Earnings: Record $745M Revenue Quarter Overshadowed by Slashed Sales Forecast  Stock Titan

Sarepta Earnings: Record $745M Revenue Quarter Overshadowed by Slashed Sales Forecast - Stock Titan

Click here to get full coverage on Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - simplywall.st

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne  simplywall.st

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - simplywall.st

Click here to get full coverage on The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low - Investor's Business Daily

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low  Investor's Business Daily

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low - Investor's Business Daily

Click here to get full coverage on Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? - Yahoo Finance

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts?  Yahoo Finance

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? - Yahoo Finance

Click here to get full coverage on Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts  Yahoo Finance

Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Click here to get full coverage on Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?  Yahoo Finance

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance

Click here to get full coverage on How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion - Yahoo Finance

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion  Yahoo Finance

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ... - Yahoo Finance

Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...  Yahoo Finance

Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ... - Yahoo Finance

Click here to get full coverage on Sarepta's ELEVIDYS Trials Paused: DMC Confirms Positive Benefit-Risk Profile - Stock Titan

Sarepta's ELEVIDYS Trials Paused: DMC Confirms Positive Benefit-Risk Profile  Stock Titan

Sarepta's ELEVIDYS Trials Paused: DMC Confirms Positive Benefit-Risk Profile - Stock Titan

Click here to get full coverage on SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? - Yahoo Finance

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?  Yahoo Finance

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%  simplywall.st

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st

Click here to get full coverage on Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now? - Yahoo Finance

Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now?  Yahoo Finance

Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now? - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth  Yahoo Finance

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Click here to get full coverage on Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today - Yahoo Finance

Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today  Yahoo Finance

Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today - Yahoo Finance

Click here to get full coverage on SRPT Quantitative Stock Analysis - Nasdaq

SRPT Quantitative Stock Analysis  Nasdaq

SRPT Quantitative Stock Analysis - Nasdaq

Click here to get full coverage on Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance

Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...  Yahoo Finance

Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance

Click here to get full coverage on Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Yahoo Finance

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More  Yahoo Finance

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Yahoo Finance

Click here to get full coverage on Could The Market Be Wrong About Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Its Attractive Financial Prospects? - simplywall.st

Could The Market Be Wrong About Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Its Attractive Financial Prospects?  simplywall.st

Could The Market Be Wrong About Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Its Attractive Financial Prospects? - simplywall.st

Click here to get full coverage on Sarepta Therapeutics (SRPT) Shares Safety Update on ELEVIDYS - StreetInsider

Sarepta Therapeutics (SRPT) Shares Safety Update on ELEVIDYS  StreetInsider

Sarepta Therapeutics (SRPT) Shares Safety Update on ELEVIDYS - StreetInsider

Click here to get full coverage on Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now - Yahoo Finance

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now  Yahoo Finance

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now - Yahoo Finance

Click here to get full coverage on 1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar - FinancialContent

1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar  FinancialContent

1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar - FinancialContent

Click here to get full coverage on Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?  Yahoo Finance

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Click here to get full coverage on Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’ - Yahoo Finance

Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’  Yahoo Finance

Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’ - Yahoo Finance

Click here to get full coverage on SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion - Yahoo Finance

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion  Yahoo Finance

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion - Yahoo Finance

Click here to get full coverage on Breakthrough: Sarepta's ELEVIDYS Gene Therapy Demonstrates Significant Gains in 8-9 Year Old Duchenne Patients - Stock Titan

Breakthrough: Sarepta's ELEVIDYS Gene Therapy Demonstrates Significant Gains in 8-9 Year Old Duchenne Patients  Stock Titan

Breakthrough: Sarepta's ELEVIDYS Gene Therapy Demonstrates Significant Gains in 8-9 Year Old Duchenne Patients - Stock Titan

Click here to get full coverage on Sarepta Expands Rare Disease Pipeline: FDA Green Light for New LGMD Trial - Stock Titan

Sarepta Expands Rare Disease Pipeline: FDA Green Light for New LGMD Trial  Stock Titan

Sarepta Expands Rare Disease Pipeline: FDA Green Light for New LGMD Trial - Stock Titan

Click here to get full coverage on SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Nasdaq

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut  Nasdaq

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Nasdaq

Click here to get full coverage on SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy - Yahoo Finance

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy  Yahoo Finance

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy - Yahoo Finance

Click here to get full coverage on Sarepta Therapeutics (SRPT) Awaits Q1 Earnings with Mixed Projec - GuruFocus

Sarepta Therapeutics (SRPT) Awaits Q1 Earnings with Mixed Projec  GuruFocus

Sarepta Therapeutics (SRPT) Awaits Q1 Earnings with Mixed Projec - GuruFocus

Click here to get full coverage on SRPT July 3rd Options Begin Trading - Nasdaq

SRPT July 3rd Options Begin Trading  Nasdaq

Sarepta Therapeutics Inc (SRPT)

Price Chart

Key Statistics

Technicals

About SRPT

Latest News

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Yahoo Finance

(SRPT) Trading Report - news.stocktradersdaily.com

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st

Advanced Charts

Top Gainers

Top Losers